{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T09:56:28Z","timestamp":1772790988306,"version":"3.50.1"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Ricerca Corrente IRCCS Istituto Auxologico Italiano"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.jaut.2016.07.003","type":"journal-article","created":{"date-parts":[[2016,8,3]],"date-time":"2016-08-03T17:42:16Z","timestamp":1470246136000},"page":"1-5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Prevention &amp; treatment of obstetrical complications in APS: Is hydroxychloroquine the Holy Grail we are looking for?"],"prefix":"10.1016","volume":"75","author":[{"given":"Pier Luigi","family":"Meroni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaut.2016.07.003_bib1","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/nrrheum.2015.86","article-title":"The evolution of drug discovery in systemic lupus erythematosus","volume":"11","author":"Wallace","year":"2015","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.jaut.2016.07.003_bib2","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jaut.2014.01.006","article-title":"Diagnosis and classification of the antiphospholipid syndrome","volume":"48\u201349","author":"Gomez-Puerta","year":"2014","journal-title":"J.\u00a0Autoimmun."},{"key":"10.1016\/j.jaut.2016.07.003_bib3","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ejogrb.2016.02.015","article-title":"Pregnancy loss: French clinical practice guidelines","volume":"201","author":"Huchon","year":"2016","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"10.1016\/j.jaut.2016.07.003_bib4","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jaut.2014.07.006","article-title":"IgG accumulates in inhibitory hippocampal neurons of experimental antiphospholipid syndrome","volume":"55","author":"Katzav","year":"2014","journal-title":"J.\u00a0Autoimmun."},{"key":"10.1016\/j.jaut.2016.07.003_bib5","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s11926-016-0573-0","article-title":"Prevention of recurrent thrombosis in antiphospholipid syndrome: different from the general population?","volume":"18","author":"Legault","year":"2016","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.jaut.2016.07.003_bib6","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1002\/art.39247","article-title":"Release of neutrophil extracellular traps by neutrophils stimulated with antiphospholipid antibodies: a newly identified mechanism of thrombosis in the antiphospholipid syndrome","volume":"67","author":"Yalavarthi","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.jaut.2016.07.003_bib7","first-page":"1","article-title":"Catastrophic antiphospholipid syndrome in pregnancy, a diagnosis that should not be missed","author":"Hoayek","year":"2016","journal-title":"J.\u00a0Matern. Fetal Neonatal Med."},{"key":"10.1016\/j.jaut.2016.07.003_bib8","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jaut.2014.06.001","article-title":"Tolerogenic dendritic cells specific for beta2-glycoprotein-I Domain-I, attenuate experimental antiphospholipid syndrome","volume":"54","author":"Zandman-Goddard","year":"2014","journal-title":"J.\u00a0Autoimmun."},{"key":"10.1016\/j.jaut.2016.07.003_bib9","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1182\/blood-2014-08-593624","article-title":"beta2-Glycoprotein I\/HLA class II complexes are novel autoantigens in antiphospholipid syndrome","volume":"125","author":"Tanimura","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jaut.2016.07.003_bib10","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/BOR.0000000000000240","article-title":"Recognition and management of antiphospholipid syndrome","volume":"28","author":"Gerosa","year":"2016","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.jaut.2016.07.003_bib11","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1097\/BOR.0000000000000200","article-title":"Update on the pathogenesis and treatment of the antiphospholipid syndrome","volume":"27","author":"Chighizola","year":"2015","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.jaut.2016.07.003_bib12","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s10787-015-0239-y","article-title":"Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases","volume":"23","author":"Rainsford","year":"2015","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.jaut.2016.07.003_bib13","doi-asserted-by":"crossref","first-page":"4380","DOI":"10.1161\/01.CIR.96.12.4380","article-title":"Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice","volume":"96","author":"Edwards","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.jaut.2016.07.003_bib14","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1055\/s-0037-1613033","article-title":"Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies","volume":"87","author":"Espinosa","year":"2002","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.jaut.2016.07.003_bib15","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jaut.2016.04.008","article-title":"Complement inhibition by hydroxychloroquine prevents placental and fetal brain abnormalities in antiphospholipid syndrome","volume":"75","author":"Bertolaccini","year":"2016","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jaut.2016.07.003_bib16","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrrheum.2011.52","article-title":"Pathogenesis of antiphospholipid syndrome: understanding the antibodies","volume":"7","author":"Meroni","year":"2011","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.jaut.2016.07.003_bib17","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1586\/1744666X.2014.968129","article-title":"Update on the current recommendations and outcomes in pregnant women with antiphospholipid syndrome","volume":"10","author":"Chighizola","year":"2014","journal-title":"Expert Rev. Clin. Immunol."},{"key":"10.1016\/j.jaut.2016.07.003_bib18","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1002\/art.39187","article-title":"Clinical characterization of antiphospholipid syndrome by detection of IgG antibodies against beta2 -glycoprotein i domain 1 and domain 4\/5: ratio of anti-domain 1 to anti-domain 4\/5 as a useful new biomarker for antiphospholipid syndrome","volume":"67","author":"Andreoli","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.jaut.2016.07.003_bib19","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/jth.12865","article-title":"Antiphospholipid syndrome: antibodies to Domain 1 of beta2-glycoprotein 1 correctly classify patients at risk","volume":"13","author":"Pengo","year":"2015","journal-title":"J.\u00a0Thromb. Haemost."},{"key":"10.1016\/j.jaut.2016.07.003_bib20","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3899\/jrheum.140760","article-title":"Obstetric antiphospholipid syndrome: has the black swan swallowed a red herring?","volume":"42","author":"Clark","year":"2015","journal-title":"J.\u00a0Rheumatol."},{"key":"10.1016\/j.jaut.2016.07.003_bib21","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1160\/TH14-05-0416","article-title":"Diagnosis and management of non-criteria obstetric antiphospholipid syndrome","volume":"113","author":"Arachchillage","year":"2015","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.jaut.2016.07.003_bib22","doi-asserted-by":"crossref","first-page":"158","DOI":"10.3899\/jrheum.141407","article-title":"Obstetric antiphospholipid syndrome: lobsters only? or should we also look for selected red herrings?","volume":"42","author":"Meroni","year":"2015","journal-title":"J.\u00a0Rheumatol."},{"key":"10.1016\/j.jaut.2016.07.003_bib23","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.autrev.2014.12.010","article-title":"The European registry on obstetric antiphospholipid syndrome (EUROAPS): a survey of 247 consecutive cases","volume":"14","author":"Alijotas-Reig","year":"2015","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jaut.2016.07.003_bib24","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1182\/blood-2013-08-522623","article-title":"Comparative incidence of pregnancy outcomes in treated obstetric antiphospholipid syndrome: the NOH-APS observational study","volume":"123","author":"Bouvier","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jaut.2016.07.003_bib25","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1160\/TH14-03-0191","article-title":"Treatment strategies and pregnancy outcomes in antiphospholipid syndrome patients with thrombosis and triple antiphospholipid positivity. A European multicentre retrospective study","volume":"112","author":"Ruffatti","year":"2014","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.jaut.2016.07.003_bib26","first-page":"299","article-title":"Combination therapy with anticoagulants, corticosteroids and intravenous immunoglobulin for women with severe obstetric antiphospholipid syndrome","volume":"32","author":"Watanabe","year":"2014","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.jaut.2016.07.003_bib27","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.autrev.2015.01.012","article-title":"The efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: data from a European multicenter retrospective study","volume":"14","author":"Mekinian","year":"2015","journal-title":"Autoimmun. Rev."},{"issue":"273","key":"10.1016\/j.jaut.2016.07.003_bib28","first-page":"e271","article-title":"The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies","volume":"214","author":"Sciascia","year":"2016","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"Suppl 1","key":"10.1016\/j.jaut.2016.07.003_bib29","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1177\/0961203393002001061","article-title":"Antimalarial drugs, pregnancy and lactation","volume":"2","author":"Parke","year":"1993","journal-title":"Lupus"},{"key":"10.1016\/j.jaut.2016.07.003_bib30","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.2165\/00002018-200124140-00004","article-title":"Antimalarial drugs in systemic lupus erythematosus: use in pregnancy","volume":"24","author":"Borden","year":"2001","journal-title":"Drug Saf."},{"key":"10.1016\/j.jaut.2016.07.003_bib31","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1002\/art.11304","article-title":"Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group","volume":"48","author":"Costedoat-Chalumeau","year":"2003","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2016.07.003_bib32","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/BOR.0000000000000055","article-title":"Rheumatoid arthritis medications and lactation","volume":"26","author":"Sammaritano","year":"2014","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.jaut.2016.07.003_bib33","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1111\/bcp.12872","article-title":"Reproductive outcomes following hydroxychloroquine use for autoimmune diseases: a systematic review and meta-analysis","volume":"81","author":"Kaplan","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.jaut.2016.07.003_bib34","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1002\/art.10150","article-title":"Evidence of transplacental passage of hydroxychloroquine in humans","volume":"46","author":"Costedoat-Chalumeau","year":"2002","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2016.07.003_bib35","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1136\/annrheumdis-2015-208840","article-title":"The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation","volume":"75","author":"Gotestam Skorpen","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2016.07.003_bib36","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1365-2125.1996.tb00190.x","article-title":"Hydroxychloroquine relative bioavailability: within subject reproducibility","volume":"41","author":"Tett","year":"1996","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.jaut.2016.07.003_bib37","first-page":"1656","article-title":"Concentration-effect relationship of hydroxychloroquine in patients with rheumatoid arthritis\u2013a prospective, dose ranging study","volume":"27","author":"Tett","year":"2000","journal-title":"J.\u00a0Rheumatol."},{"key":"10.1016\/j.jaut.2016.07.003_bib38","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1002\/art.10307","article-title":"Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis","volume":"46","author":"Munster","year":"2002","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2016.07.003_bib39","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1002\/art.22156","article-title":"Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus","volume":"54","author":"Costedoat-Chalumeau","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2016.07.003_bib40","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1002\/art.39194","article-title":"Determinants of hydroxychloroquine blood concentration variations in systemic lupus erythematosus","volume":"67","author":"Jallouli","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.jaut.2016.07.003_bib41","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/art.39402","article-title":"Association of polymorphisms of Cytochrome P450 2D6 with blood hydroxychloroquine levels in patients with systemic lupus Erythematosus","volume":"68","author":"Lee","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.jaut.2016.07.003_bib42","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1136\/annrheumdis-2012-202322","article-title":"Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study)","volume":"72","author":"Costedoat-Chalumeau","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2016.07.003_bib43","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/s11239-014-1061-x","article-title":"Recurrent thrombosis prevention with intravenous immunoglobulin and hydroxychloroquine during pregnancy in a patient with history of catastrophic antiphospholipid syndrome and pregnancy loss","volume":"38","author":"Mar","year":"2014","journal-title":"J.\u00a0Thromb. Thrombolysis"},{"key":"10.1016\/j.jaut.2016.07.003_bib44","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1136\/ard.55.7.486","article-title":"Hydroxychloroquine and lupus pregnancy: review of a series of 36 cases","volume":"55","author":"Buchanan","year":"1996","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2016.07.003_bib45","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1160\/th15-06-0491","article-title":"The efficacy of hydroxychloroquine in altering pregnancy outcome in women with antiphospholipid antibodies. Evidence and clinical judgment","volume":"115","author":"Sciascia","year":"2016","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.jaut.2016.07.003_bib46","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1177\/0961203315591027","article-title":"Impact of hydroxychloroquine on preterm delivery and intrauterine growth restriction in pregnant women with systemic lupus erythematosus: a descriptive cohort study","volume":"24","author":"Leroux","year":"2015","journal-title":"Lupus"},{"key":"10.1016\/j.jaut.2016.07.003_bib47","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood-2009-04-213520","article-title":"Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug","volume":"115","author":"Rand","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jaut.2016.07.003_bib48","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/humupd\/dmu049","article-title":"Antiphospholipid antibodies and the placenta: a systematic review of their in\u00a0vitro effects and modulation by treatment","volume":"21","author":"Tong","year":"2015","journal-title":"Hum. Reprod. Update"},{"key":"10.1016\/j.jaut.2016.07.003_bib49","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/aji.12184","article-title":"Effect of hydroxychloroquine on antiphospholipid antibody-induced changes in first trimester trophoblast function","volume":"71","author":"Albert","year":"2014","journal-title":"Am. J. Reprod. Immunol."},{"key":"10.1016\/j.jaut.2016.07.003_bib50","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1111\/jth.12570","article-title":"Hydroxychloroquine restores trophoblast fusion affected by antiphospholipid antibodies","volume":"12","author":"Marchetti","year":"2014","journal-title":"J.\u00a0Thromb. Haemost."},{"key":"10.1016\/j.jaut.2016.07.003_bib51","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J.\u00a0Thromb. Haemost."}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841116301019?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841116301019?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T08:14:34Z","timestamp":1760256874000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841116301019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":51,"alternative-id":["S0896841116301019"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2016.07.003","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevention & treatment of obstetrical complications in APS: Is hydroxychloroquine the Holy Grail we are looking for?","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2016.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}